| European Medicines Agency Warns on Psychiatric Side Effects on Anti-Obesity Drug Acomplia (CardiovascularWeb News) July 21, 2007 Acomplia (rimonabant) is the first in a new class of anti-obesity drugs that suppresses a person’s appetite by blocking the CB1 cannabinoid receptor in the brain. It has the potential in reducing cardiovascular complications in obese patients. However, the European Medicines Agency (EMEA) said that Acomplia (Sanofi-Aventis) has psychiatric side effects such as depression and suicidal thoughts in a subgroup of patients. EMEA now recommends against the use of drug in patients with major depression or undergoing anti-depression therapy. In the meantime, they have decided Acomplia can stay on the market because of its benefit to obese patients but the drug should carry a warning label telling physicians and patients that the therapy should discontinue if signs of depression appear. Rimonabant, to be marketed under the name Zimulti in the US market, was also not recommended by US advisory panel in United States last month because of its psychiatric effect. |
July 21, 2007
 | |  | |  |
Cardiovascularweb
|
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |